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Anaplastic thyroid cancer (ATC) has a median survival less than 5 months and, to date, no effective therapy exists. Taxanes
have recently been stated as the main drug treatment for ATC, and the histone deacetylase inhibitor valproic acid efficiently
potentiates the effects of paclitaxel in vitro. Based on these data, this trial assessed the efficacy and safety of the combination of
paclitaxel and valproic acid for the treatment of ATC. This was a randomized, controlled phase II/III trial, performed on 25 ATC
patients across 5 centers in northwest Italy. The experimental arm received the combination of paclitaxel (80mg/m2/weekly) and
valproic acid (1,000mg/day); the control arm received paclitaxel alone. Overall survival and disease progression, evaluated in terms
of progression-free survival, were the primary outcomes. The secondary outcome was the pharmacokinetics of paclitaxel. The
coadministration of valproic acid did not influence the pharmacokinetics of paclitaxel. Neither median survival nor median time
to progression was statistically different in the two arms. Median survival of operated-on patients was significantly better than that
of patients who were not operated on. The present trial demonstrates that the addition of valproic acid to paclitaxel has no effect
on overall survival and disease progression of ATC patients. This trial is registered with EudraCT 2008-005221-11.
1. Introduction
Anaplastic thyroid cancer (ATC) is one of the most lethal
solid tumors and it usually has a rapidly fatal clinical course,
its median survival being less than 5 months from diagnosis.
Although rare (2% of all thyroid cancers), ATC accounts for
14–50% of total mortality for thyroid cancer, with survival
rates of 10–20% at one year and less than 2% at ten years
[1]. In the last decade, multimodality treatment (surgery
if feasible, followed by radiotherapy in combination with
various chemotherapeutic drugs) has been recommended
as the optimal approach, but the results of such treatment
still remain poor without significant impact on the survival
rates and important side effects [2, 3]. ATC is classified
as stage IV by the International Union Against Cancer
and American Joint Commission on Cancer classifications
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and the use of systemic chemotherapy is frequently recom-
mended independently of the presence of distant metas-
tases. Taxanes (paclitaxel and docetaxel) are considered the
first-line chemotherapeutic agents, for ATC treatment [4],
also if the promising results obtained in earlier studies [5]
were not unanimously confirmed by subsequent reports
[6, 7]. Chemotherapy can be particularly harmful in older
patients, like those typically affected by ATC [8], and a dose
reduction due to hematological and neurological toxicity is
often necessary; therefore its use may be cumbersome in the
clinical practice. The use of biological therapy, either with
tyrosine kinase inhibitors or with other targeted therapies
(e.g., fosbretabulin and everolimus), was advised in ATC but
the results of clinical trials have been discouraging [9]. As a
consequence, no standard effective medical therapy for ATC
exists to date. Deacetylase inhibitors (DCI) represent a class
of therapeutic agents with broad activity against cancer cells,
namely, cytotoxic effects, induction of cell differentiation,
and synergism with established and experimental cancer
therapeutics [10]. In preclinical studies, the combination
therapy of DCIwith chemotherapeutic agents enhanced drug
therapeutic efficacy against ATC. Suberoylanilide hydrox-
amic acid (SAHA), approved by FDA for the treatment of
cutaneous T cell lymphoma, has shown anticancer activity
in vitro and in vivo alone or in combination with paclitaxel,
doxorubicin, or Paraplatin [11], but unfortunately it resulted
as ineffective in a phase II study in patients with advanced
thyroid cancer [12]. Belinostat (PXD101) represses thyroid
cancer proliferation and exerts synergistic effects in combina-
tion with doxorubicin and paclitaxel [13]. In both in vitro and
in vivo models of ATC, panobinostat (LBH589) has shown
cytotoxic activity [14], suppressing migration and invasion
[15] and inducing radioiodine cytotoxicity [16]. Very recently,
SP600125, a small compound acting on the ROCK/HDAC6
pathway, has been demonstrated to selectively induce cell
death in undifferentiated thyroid cancer cell lines, making
it a good candidate for developing new drugs against ATC
[17]. We previously demonstrated that the DCI valproic acid
(VPA) efficiently potentiates the effects of doxorubicin [18]
and paclitaxel (TAX) in vitro [19].These findings provided the
rationale for the present randomized, controlled, phase II/III,
multicenter clinical trial with the aim of assessing the efficacy
and safety of TAX with (experimental arm) or without VPA
(control arm) for the treatment of patients affected by ATC.
2. Patients and Methods
2.1. Patients. The study was performed across 5 centers in
northwest Italy between 2009 and 2012, on patients of both
genders affected by ATC and eligible for treatment with
TAX. The diagnosis was obtained by cytological exami-
nation of specimens following fine-needle aspiration and
was confirmed by histologic examination in all patients
who underwent surgery. Examination was performed by
two different pathologists with proven experience in thyroid
cancer. Inclusion criteria were (a) patients with radiologically
or clinically confirmed disease progression during or after
multimodal therapy (surgery, if performed, first-line systemic
chemotherapy with doxorubicin and cisplatin, and external
beam radiation (EBR)); (b) patients not eligible for surgery or
EBR because of tumor local invasion or severe comorbidities.
Patients had to have an Eastern CooperativeOncologyGroup
(ECOG) Performance Score <3. Liver function had to be
adequate as evidenced by serum total bilirubin <2x the upper
limit of normal (ULN) (<3x ULN in patients with liver
metastases); AST (aspartate aminotransferase)/ALT (alanine
aminotransferase) <3x the ULN for the local reference lab-
oratory (<5x the ULN for patients with liver metastases).
Exclusion criteria were liver and/or kidney failure; thrombo-
cytopenia and/or thrombocytopathy; treatment with aspirin
or antiplatelet agents; treatment with antipsychotic drugs;
impossibility of obtaining an informed consent due to
impaired consciousness; pregnant or breastfeeding women;
fertile women not taking contraceptive pills. The trial was
approved by the local ethic committee for each study site.
Patients or their legal representatives needed to be able to
read, understand, and provide written informed consent
to participate in the trial, according to the Declaration of
Helsinki.
2.2. Study Design. Patients were openly randomized into
two arms: the experimental arm received the combination
of TAX (80mg/m2) and VPA (1,000mg/day); the control
arm received TAX alone (80mg/m2). TAX was administered
weekly intravenously, dose reduction being allowed in case of
hematological or gastrointestinal toxicity; VPA was admin-
istered daily p.o. in two divided doses of 500mg. In the
absence of disease progression, patients of both groups were
treated up to 18 chemotherapy cycles. Primary outcomeswere
(1) overall survival and (2) disease progression, evaluated
in terms of progression-free survival (PFS). The extent of
thyroid neoplasia and secondary lesions were assessed at the
beginning of treatment by computer tomography (CT) scans
of head, neck, chest, and abdomen. Local recurrence or lymph
node metastases were evaluated also by high definition neck
ultrasonography (US). CT and US were repeated every 6–
8 weeks, to assess the response to treatment according to
the modified World Health Organization (WHO) criteria:
(a) complete response (CR), disappearance of all known
lesions and no new lesions; (b) partial response (PR), ≥50%
decrease in the sum of the products of diameters of lesions;
(c) disease stabilization (SD), absence of CR or PR, without
any evidence of disease progression; (d) progressive disease
(PD), ≥25% increase in the size of one or more measurable
lesions or the appearance of new lesions. Modifications of
WHO criteria refer to the persistence of response for 4 weeks
after evaluation; this last criterion cannot be applied to ATC,
whose clinical doubling time is very rapid, up to three days.
Clinical follow-up was performed every two weeks and will
last up to 12 months. (3) Quality of life is evaluated using the
EORTC QLQC30 v3 ranking every six weeks.
2.3. Safety. Hemogram, serum biochemistry, and electrolyte
levels were measured before each chemotherapy cycle and
when clinically indicated; toxicity was evaluated according
to the Common Toxicity Criteria (CTC). A temporary sus-
pension of TAX treatment, followed by a 25% reduction at
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the restart, was foreseen in the presence of mucositis (Grade
3); hematologic toxicity (Grade 2); gastrointestinal toxicity
(Grade 3); neurotoxicity (Grade 3); cardiac toxicity (Grade
3); muscle and skeletal toxicity (Grade 3). In the presence
of Grade 4 toxicity or in case of severe allergic reaction,
treatment was definitively stopped.
2.4. Pharmacokinetics. The secondary outcome of the study
was the pharmacokinetics of TAX. During the first chem-
otherapy cycle, the pharmacokinetic parameters of TAX
(𝐶max, AUC, 𝐾el, 𝑡1/2, clearance, and 𝑉ss) were evaluated in
20 patients (10 receiving TAX; 10 receiving VPA + TAX) by a
noncompartmental pharmacokinetic analysis performed by
Kinetica 2000 4.1.1 software (InnaPhase Corp., Philadelphia,
USA). Blood samples were collected in heparinized tubes,
from a large vein in the arm opposite that receiving the
drug infusion, at the following times: time 0 (immediately
before TAX infusion), 1.5 hours (half infusion), 3 hours (end
of infusion), 4 hours, 5 hours, and 6 hours. Blood samples
were centrifuged immediately for 10min at 1,000×g at room
temperature and the resulting plasma was frozen and stored
at −80∘C until analysis.
TAX plasma concentrations were measured according
to a procedure described elsewhere [20]. Briefly, a volume
of 200𝜇L of acetonitrile, 300 𝜇L of deionized water, and
5mL of tertbutylmethylether was added to 100 𝜇L of plasma
samples in borosilicate glass tubes.Themixture was vortexed
for 30 sec and centrifuged at 2,500×g for 15min. Upon
centrifugation, 3mL of the organic layer was transferred
to a clean glass tube and evaporated to dryness under
nitrogen. The residue was then reconstituted with 200𝜇L of
60% acetonitrile in deionized water and mixed on a vortex
mixer for 90 sec; then 100 𝜇L of the reconstituted sample was
injected into the HPLC system equipped with a Symmetry
C18 column (250 × 4.6mm i.d., particle size 5 𝜇m) and a
Symmetry C18 guard column supplied by Waters (Vimod-
rone,Milan, Italy). Chromatographic analysis was performed
at room temperature (20 ± 2∘C) by isocratic elution with a
mobile phase consisting in a mixture of acetonitrile—0.1%
phosphoric acid in deionized water (60 : 40, v/v) (Milli-Q
Plus System, Millipore, Milford, MA, USA) at a flow-rate of
1.0mL/min. UV detection wavelength was 227 nm and TAX
retention time was about 10min. TAX concentrations were
determined from the peak area ratios versus a standard curve
obtained with the same procedure. The limit of quantitation
for this method was 5 ng/mL.
2.5. Valproic Acid Levels. Serum levels of VPAwere evaluated
in 11 patients at 2 and 4 weeks after they started VPA
treatment. Drug measurement was performed using the
Dimension Vista System (Siemens, Healthcare, Erlangen,
Germany). The therapeutic range was 50–100 g/mL.
2.6. Statistics. Median and range were reported for demo-
graphic and clinical variables descriptions. Probabilities of
overall survival (OS) and PFS associated with combination
treatment (VPA + TAX) versus TAX treatment alone were
estimated from the time of enrollment using Kaplan-Meier
method; log-rank test compared distributions of the two
groups. Assuming that the predicted 1 year overall survival of
patients treated with TAX alone is 0.1% and that the addition
of VPA may lead to an overall survival of 20%, 22 patients
could permit us to demonstrate a significant difference in the
primary outcomes, accepting an error of 0.05 and 80% power.
The occurrence of death within 365 days from enrollment
was considered the event for estimated OS. Patients who
were alive after 365 days were censored for the survival
analysis. PFS was defined as the time to disease progression
as evaluated by CT. Patients with clinical events unrelated to
treatments or disease progression were censored.
The Mann–Whitney nonparametric test was used to
compare pharmacokinetic values of the two different groups
of patients; statistical evaluation was performed using Instat
3.05 software (Graphpad, San Diego, USA).
3. Results
3.1. Patients. Patient characteristics are reported in Table 1.
The trial enrolled 25 patients; 14 patients were randomized
to the TAX arm; 11 patients were randomized to the VPA +
TAX arm. 13 patients were males (8 in the TAX arm and 5 in
the TAX + VPA arm); 12 patients were females (6 in the TAX
arm and 6 in the TAX + VPA arm). At diagnosis, median age
was 70 years (range 44–83) (73.5 for the TAX arm [range 62–
83] and 66 for the TAX + VPA arm [44–80]). Disease stage
was IV-A in 2 patients (1 in the TAX arm and 1 in the TAX
+ VPA arm), IV-B in 6 patients (1 in the TAX arm and 5 in
the TAX + VPA arm), and IV-C in 17 patients (12 in the TAX
arm and 5 in the TAX + VPA arm). Lymph node metastases
were present in 9 patients (5 in the TAX arm and 4 in the
TAX + VPA arm); lung metastases were present in 9 patients
(7 in the TAX arm and 2 in the TAX + VPA arm). No brain
metastases were present at diagnosis. 8 patients (7 at stage 4C
and 1 at stage 4A) did not undergo thyroidectomy (6 in the
TAX arm and 2 in the TAX + VPA arm); while 17 patients (10
at stage IV-C, 6 at stage IV-B, and 1 at stage IV-A) underwent
surgery (8 in the TAX arm and 9 in the TAX + VPA arm).
One patient, randomized to the TAX + VPA arm, died only 6
days after the informed consent and, therefore, was excluded
from the statistical analysis.
3.2. Efficacy. Median survival of the 14 patients treated with
TAXwas 148 days, whereas median survival of the 10 patients
treated with VPA + TAX was 122 days (𝑃 = 0.9) (Figure 1(a)).
Median time to progression in the TAX group was 51 days,
versus 48 days in the VPA + TAX group (𝑃 = 0.6)
(Figure 1(b)). Median survival of patients who had been
operated on was significantly better than that observed of
patients who had not (203 days versus 143 days, 𝑃 = 0.03)
(Figure 2(a)). Median time to progression of patients who
had been operated on was not significantly better than that
observed in patients who had not (52 days versus 44 days,
𝑃 = 0.6) (Figure 2(a)).
3.3. Safety. The oral administration of 1,000mg valproate
given once daily induced the raise of valproate blood levels to
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Table 1: Patient characteristics.
TAX VPA + TAX
Number of enrolled patients 14 11
Gender
(i) Male 8 5
(ii) Female 6 6
Age (years)
(i) Median 73.5 66
(ii) Range 62–83 44–80
Disease stage
(i) 4A 1 1
(ii) 4B 1 5
(iii) 4C 12 5
Distant metastasis
(i) Lymph nodes 5 4
(ii) Lung 7 2
Previous therapy
(i) Radiotherapy 6 7
(ii) Chemotherapy 4 7
(iii) Thyroidectomy (incomplete) 7 ∗R0/R1 (1 R2) 8 ∗R0/R1 (1 R2)
∗R0/R1: macroscopically complete resection; R2 resection with minimal macroscopical residual tumor.
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Figure 1: Kaplan-Meier plots of overall survival (a) and progression-free survival (PFS, (b)) of patients with anaplastic thyroid cancer treated
with VPA + TAX (-) versus TAX (- -).
values within the proper therapeutic range for epilepsy treat-
ment after two weeks of treatment (67 g/mL; range 50–72).
No increase in serum values of liver enzymes was observed.
For 24/25 patients enrolled in the study, the scheduled
dose of TAX was maintained. In one patient, TAX was
reduced to 75%, as a consequence of allergic reaction during
the first TAX infusion. No severe adverse effect was observed.
The median duration of treatment was not statistically dif-
ferent between the group treated with VPA + TAX (73 days;
range 36–183 days) and the group treated with TAX alone
(102 days; range 31–300). For all the patients enrolled, therapy
was administered as planned by study design, until clinical
progression or death.
3.4. Pharmacokinetics. Figure 3 shows the median plasma
profile of TAX for patients treated with TAX alone or with
VPA + TAX. Table 2 summarizes the medians of the main
pharmacokinetic parameters of TAX obtained from the plas-
matic curves for both control and experimental groups. The
results of Mann–Whitney test showed no difference between
the two groups, demonstrating that the coadministration of
VPA did not influence the pharmacokinetics of TAX.
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Figure 2: Kaplan-Meier plots of overall survival (a) and progression-free survival (PFS, (b)) of patients with anaplastic thyroid cancer who
underwent total thyroidectomy (-) versus no thyroid surgery (- -) (𝑃 < 0.05).
Table 2: Pharmacokinetic parameters.
Pharmacokinetic parameters Median (range) 𝑃 value (Mann–Whitney)
TAX VPA + TAX
𝐶max (ng/mL) 1155 (767–1749) 1134 (608–1565) 0.85
AUCtot (ng × h/mL) 3490 (2177–4321) 3434 (2050–4137) 0.68
𝐾el (1/h) 0.34 (0.18–0.56) 0.49 (0.41–0.56) 0.05
𝑡
1/2
(h) 2.03 (1.24–3.94) 1.42 (1.25–1.69) 0.05
Cl (mL/h) 39858 (30189–71196) 41819 (30898–71012) 0.91
𝑉ss (mL) 52138 (43138–147388) 61452 (34164–142622) 0.58
4. Discussion
An effective treatment for ATC, one of the most lethal
cancers, has not been established yet [21, 22]. The American
Thyroid Association guidelines [23] recommend a multi-
modal approach including surgery, radiation, and systemic
chemotherapy for patients with stage IV-A/IV-B ATC, and
this approach showed some efficacy also in patients with stage
IV-C disease in our experience [24]. More recent NCCN
guidelines recommend docetaxel/doxorubicin schemes with
or without EBR therapy and suggest TAX 60–90 i.v. mg/m2/
weekly as the most effective single therapeutic agent. Both
guidelines conclude that current systemic treatments lead to
poor outcome and fail in improving survival or PFS. Several
novel therapies have been evaluated in clinical trials, such
as vascular disrupting agents (fosbretabulin, combretastatin,
and crolibulin) and multitargeted therapies (bevacizumab,
a number of tyrosine kinase inhibitors such as sorafenib,
sunitinib, imatinib, and pazopanib). None of these agents
showed any relevant effect on survival or PFS, being similar
to those obtained with the traditional multimodal approach.
These discouraging results were obtained mainly from
observational studies performed in small series of patients.
The present study is a rare example of an interventional
randomized trial comparing one established treatment (TAX)
with a combination one (TAX plus VPA).
The decision to combine VPA with TAX in the present
clinical trial stems from data obtained (by our group) with
VPA as histone deacetylase inhibitor. The advantage of
using VPA, a potent anticonvulsant widely used to treat
epilepsy and mood disorders that acts as DCI at therapeutic
concentrations [25, 26], is that it produces only mild adverse
effects in humans, even when serum levels exceed the normal
therapeutic range. Besides histones and other nonhistone
proteins, 𝛼-tubulin is also a substrate of histone deacetylases
[27]. In line with this, we reported elsewhere that the
combination of VPA with TAX enhanced TAX cytostatic
and cytotoxic activity in ATC cell lines [19]. The effect was
reached with VPA at a dose of 0.7mM, which corresponds
to plasma levels within the therapeutic range in patients
treated for epilepsy and is without any serious side effects.
Suppression of microtubule dynamics is recognized as the
mechanismbywhichTAXblocksmitosis and kills tumor cells
[28]: rapid dynamics ensure timely and accurate chromosome
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Figure 3: Median plasmatic paclitaxel concentrations for patients
treated with TAX alone (VPA 0) or with VPA + TAX (VPA 1000).
Boxes = 25th and 75th percentiles; bars =min and max values.
movement; and our previous in vitro data clearly showed that
VPA induced tubulin acetylation and maximally potentiated
the acetylating activity of TAX. Beyond our previous in
vitro data, several groups have investigated the possibility
of combining VPA with different chemotherapeutic agents
in patients with leukaemia and solid tumors. VPA has
been shown to potentiate the activity of doxorubicin in
patients with breast cancer [29]; moreover, in patients with
metastatic tumors, the combination of VPA and epirubicin
has been shown to be effective andwell tolerated [30]. Finally,
data are available from phase I/II clinical trials with VPA
and 5-azacitidine in myelodysplastic syndrome [31]. On the
contrary, to the best of our knowledge, no other clinical trials
are available on the efficacy of the combination of VPA and
TAX.
Unfortunately, the encouraging results obtained in vitro
on the enhancing action of VPA on TAX were not confirmed
in the clinical setting of our ATC patients. In fact, mean
overall survival and PFS were comparable in the 2 groups
of patients, and they did not differ from those reported
in other previous series of patients treated with traditional
multimodal treatment. This observation is not new, since,
for several therapeutic agents such as fosbretabulin [32, 33]
and combretastatin [34] and, more recently, for sorafenib
[9] and pazopanib [35], the promising effects described in
experimental models of ATC were not confirmed by strong
outcomes in clinical trials. The median survival observed in
our study did not differ from that reported in clinical trials
of fosbretabulin plus paclitaxel/carboplatin (4.7 months),
sorafenib (3.9 months), combretastatin (5.2 months), and
pazopanib (111 days). The number of patients treated in a
second-line setting was greater in the VPA + TAX arm
(8/10) than in the TAX arm (4/14) but the performance
status did not differ between the two groups. However, the
possibility that more chance of resistance to cytotoxic agents
in patients treated in second-line setting could explain the
lack of significant differences between VPA + TAX and TAX
arm may not be inferred by our data and remain speculative.
Patients treated with TAX plus VPA did not experience
more side effects than those treated only with TAX. Drug
interaction between TAX and antiepileptic drugs has been
previously described [36]. TAX is metabolized extensively by
CYP2C8 and, to a smaller extent, by CYP3A4; furthermore
TAX is a substrate of P-gp. TAX is therefore susceptible to
interactions with drugs that induce or inhibit these proteins.
As some preclinical in vitro and in vivo experiments demon-
strated that VPA is able to slightly inhibit CYP3A4 (Ki =
7975 𝜇M) and to induce the overexpression of P-gp, therefore
a pharmacokinetic interaction between the two drugs could
occur in the patients of the experimental arm [37, 38]. Our
results demonstrated that pharmacokinetic parameters of
TAX showed no difference between the control and experi-
mental arms, suggesting no pharmacokinetic interaction of
VPA that could influence TAX clinical efficacy.
In conclusion, regardless the promising preclinical
results, the present trial demonstrated that the combination
of VPA and TAX was not superior to TAX alone.
Nevertheless, our results did not differ from those observed
in other studies in patients with advanced ATC.
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